MRK Stock Recent News
MRK LATEST HEADLINES
Merck & Co., Inc. (MRK) Management Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript)
Merck & Co., Inc. (NYSE:MRK ) 6th Annual Evercore ISI HealthCONx Conference Transcript November 30, 2023 1:20 PM ET Executives Dr. Eliav Barr - Senior Vice President, Head, Global Clinical Development and CMO Peter Dannenbaum - Vice President, Investor Relations Analysts Umer Raffat - Evercore Umer Raffat Thank you. Listen, thank you guys for being here.
Positive data from Merck's (MRK) phase III study on V116, an investigational, 21-valent pneumococcal conjugate vaccine, supports the immunogenicity of V116 compared to standard of care.
Merck & Co. Inc. MRK said Tuesday its board has raised its quarterly dividend to 77 cents. The dividend was previously 73 cents.
Merck is a legacy drugmaker with a history of fat margins and occasional robust growth. The company is entering a new growth phase, making it a good investment opportunity. Merck has a low forward P/E ratio and strong growth prospects, making it suitable for retirees and investors approaching retirement.
Merck (MRK) has been a shareholder in Caraway Therapeutics since 2018 through its MRL Ventures Fund.
Merck reported positive quarterly earnings with 6.7% year-over-year revenue growth and improved operating margin. The company generated strong leveraged free cash flow and reduced financial leverage, improving its net debt position. Merck has raised dividends for 12 consecutive years with an average growth rate nearing 10%.
The U.S. health regulator's advisers on Friday did not recommend Merck's drug for the treatment of chronic cough.
Following this approval, Merck's (MRK) Keytruda is approved for seven gastrointestinal cancers. Overall, the drug is approved for 38 indications in the country.
Merck & Co Inc (NYSE:MRK) announced on Thursday that its anti-PD-1 therapy Keytruda in combination with chemotherapy has been approved by the U.S. Food and Drug Administration (FDA) for gastric cancer. This marks the 38th indication to win approval for Keytruda regimens in the United States and the seventh gastrointestinal cancer indication, Merck highlighted.
Merck MRK, +0.63% said late Thursday that the Food and Drug Administration has approved its star cancer drug Keytruda as treatment for some adult gastrointestinal cancers, alongside chemotherapy. Approval was based on results from an advanced-stage trial that “demonstrated significant improvement in overall survival in these patients versus chemotherapy alone,” the drug company said.